The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines ...

The decision comes months after the FDA had suspended the vaccine’s license. One analyst speculated the company might shelve the product altogether.

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug ...

The “Great Healthcare Plan” is vague, but would send money directly to ACA enrollees and entrench the pricing deals the ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

More than 3,000 prescriptions were written for Novo’s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached ...

AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...

Startups raised $14.2 billion last year, the highest funding total since 2022. Health AI companies collected 54% of total ...

Co-founded by Jennifer Doudna and Fyodor Urnov, the company intends to simultaneously develop many gene editing treatments ...

By the end of March, the agency could approve multiple “national priority” voucher winners, as well as a gene therapy it ...

Arrowhead’s RNA drugs could aid with “high-quality” weight loss, according to one analyst. Elsewhere, the PD-1/VEGF field got less crowded and Amgen and Lilly struck startup deals.